TD Private Client Wealth LLC Invests $169,000 in Edwards Lifesciences Corporation $EW

TD Private Client Wealth LLC bought a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 2,156 shares of the medical research company’s stock, valued at approximately $169,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Arlington Trust Co LLC raised its holdings in Edwards Lifesciences by 1.2% in the first quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company’s stock valued at $804,000 after acquiring an additional 135 shares in the last quarter. Valeo Financial Advisors LLC lifted its position in shares of Edwards Lifesciences by 2.8% during the 1st quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company’s stock worth $372,000 after purchasing an additional 142 shares during the last quarter. Versant Capital Management Inc lifted its position in shares of Edwards Lifesciences by 9.3% during the 1st quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company’s stock worth $123,000 after purchasing an additional 145 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Edwards Lifesciences by 0.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock worth $2,170,000 after purchasing an additional 145 shares during the last quarter. Finally, Leo Wealth LLC lifted its position in shares of Edwards Lifesciences by 1.2% during the 1st quarter. Leo Wealth LLC now owns 12,488 shares of the medical research company’s stock worth $905,000 after purchasing an additional 150 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider directly owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.34% of the company’s stock.

Edwards Lifesciences Trading Up 1.4%

Shares of Edwards Lifesciences stock opened at $76.34 on Monday. Edwards Lifesciences Corporation has a 52-week low of $64.00 and a 52-week high of $83.00. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The company’s 50-day simple moving average is $78.50 and its 200-day simple moving average is $75.78. The firm has a market cap of $44.82 billion, a price-to-earnings ratio of 10.98, a price-to-earnings-growth ratio of 3.67 and a beta of 1.07.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period in the previous year, the business posted $0.70 earnings per share. The business’s revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on EW. BTIG Research raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a research report on Tuesday, July 29th. Piper Sandler lifted their price objective on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, July 25th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the stock a “buy” rating in a research report on Friday, July 25th. William Blair raised shares of Edwards Lifesciences to a “strong-buy” rating in a research report on Friday, July 25th. Finally, Wall Street Zen cut shares of Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research report on Monday. Three research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $86.61.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.